Theranostic Implications of Nectin-4 Oncoprotein in Gynecologic Cancers: A Review

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 269, P. 155913 - 155913

Published: March 15, 2025

Language: Английский

---

Immune inhibitory receptor agonist therapeutics

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16

Published: March 26, 2025

The immune system maintains the health of an organism through complex sensing and communication mechanisms. Receptors on surface cells respond to stimuli resulting in activity described at its most basic as inhibitory or stimulatory. Significant progress therapeutic intervention has occurred by modulating these pathways, yet much remains be accomplished. Therapeutics that antagonize, block, receptor (IIR) such checkpoint inhibitors cancer are a key example. Antagonism stimulatory receptors (ISRs) for dysregulated inflammation autoimmunity have received significant attention. An alternative strategy is agonize, induce signaling, pathways treat disease. Agonism ISRs been employed with some success disease settings, but agonist therapeutics IIRs great, untapped potential. This review discusses highlights recent advances pre-clinical clinical designed agonize IIR diseases. In addition, understanding agonists based cellular level either suppression (SuSt), new concept, suppressive (SuSu) proposed.

Language: Английский

---

Advances in classification and treatment of primary cutaneous lymphomas

Annals of Hematology, Journal Year: 2025, Volume and Issue: unknown

Published: March 25, 2025

Language: Английский

---

Bioengineered extracellular vesicles presenting PD-L1 and Gal-9 to ameliorate new-onset primary ovarian insufficiency (POI)

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 162635 - 162635

Published: April 1, 2025

Language: Английский

---

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Nov. 13, 2024

Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due complex manufacturing processes, limited vivo persistence, and transient therapeutic effects. In CAR-immune cells induced by gene delivery systems loaded with CAR genes gene-editing tools have shown efficiency for anti-tumor immunotherapy. situ programming of autologous immune avoids the safety concerns allogeneic cells, manufacture could be standardized. Therefore, editing generation might potentially overcome abovementioned limitations current therapy. This review mainly focuses on structures, tools, techniques applied immunotherapy help design develop The recent applications both hematologic malignancies are investigated. To sum up, holds promise offering a practical, cost-effective, efficient, safe, widely applicable approach next-generation

Language: Английский

---

Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(21), P. 11384 - 11384

Published: Oct. 23, 2024

Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline tumor biology behind actual potential drug targets address challenges drawbacks coupled with their (potential) use. Therapeutic modalities are discussed, including small-molecule inhibitors, naked antibodies, antibody-drug conjugates, chimeric antigen receptors, bispecific antibodies T-cell engagers, immune checkpoint inhibitors. Candidate drugs explored in ongoing trials diverse toxicity issues refractoriness drugs. According literature DLBCL, promise for new therapeutic lies epigenetic alterations, receptor NF-κB pathways. present putative hiding lipid pathways, ferroptosis, gut microbiome that could be used addition immuno-chemotherapy improve general health status patients, thus increasing chance being cured. It may time devote more effort exploring metabolism discover novel druggable targets. We also performed bibliometric knowledge-map analysis published from 2014-2023.

Language: Английский

---

Bioengineered extracellular vesicles presenting PD-L1 and Gal-9 to ameliorate new-onset primary ovarian insufficiency (POI)

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 2, 2024

Primary ovarian insufficiency (POI) is a clinical syndrome of dysfunction characterized by premature exhaustion primordial follicles, which causes infertility and dysfunctions many other organ systems including sexuality, bones, the cardiovascular system, neurocognition. An important factor in development POI immune dysregulation, results augmented T cell response ovary. Thus, modulation infiltrated lymphocytes exogenous PD-L1 or Gal-9 an ideal approach for treating POI. Herein, we genetic engineered human umbilical cord mesenchymal stem cells (hucMSCs) derived extracellular vesicles (EVs) overexpressing Gal-9, could restrict activity autoreactive protect from destruction. Moreover, PD-L1-Gal-9 EVs prominently promoted effector apoptosis vitro, reversed decreased AMH mice as well declined proportion CD8+ infiltrating ovaries, contributed to preventing progression preserving residual fertility.

Language: Английский

---

The future of interleukin gene therapy in head and neck cancers

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 17

Published: Sept. 18, 2024

Head and neck cancer (HNC), primarily head squamous cell carcinomas, originates from the epithelium in areas like oral cavity, lip, larynx, oropharynx. With high morbidity impacting critical functions, combined treatments surgery, radiation, chemotherapy often fall short advanced stages, highlighting need for innovative therapies.

Language: Английский

---

Innovative strategies in genitourinary cancer: the role of oncolytic viruses

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Oct. 11, 2024

Urinary tumors pose a significant health threat because of their high prevalence and recurrence rates. Despite the availability various treatment options, many patients poorly respond to traditional therapies, highlighting urgent need for alternative approaches. Oncolytic viruses are promising therapeutic agents. These exploit unique characteristics cancer cells specifically target destroy them, thereby triggering potent antitumor immune responses. This review delves into recent advancements future prospects oncolytic viruses, focusing on application in renal, bladder, prostate cancers. By discussing practical implications potential different including cowpox virus, adenovirus, measles coxsackievirus, reovirus, we pave way further exploration refinement this exciting field.

Language: Английский

---

A systematic review of cardiovascular toxicities induced by cancer immune therapies: underlying mechanisms, clinical manifestations and therapeutic approaches

Seminars in Cancer Biology, Journal Year: 2024, Volume and Issue: 106-107, P. 179 - 191

Published: Oct. 22, 2024

Language: Английский

---